F. Bidard

A. Vincent-Salomon, F. Reyal, Y. Rycke, 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

J. Soria, F. Bidard, J. Pierga, 2017, European journal of cancer.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

F. Bertucci, J. Lemonnier, J. Bonneterre, 2016, The Lancet. Oncology.

Clinical utility of circulating tumor cells: an update

F. Bidard, J. Pierga, A. Vasseur, 2020, Molecular oncology.

FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool.

J. Klijanienko, F. Bidard, J. Pierga, 2015, Lab on a chip.

The Genomic Landscape of Male Breast Cancers

Melissa P. Murray, C. Hudis, J. Reis-Filho, 2016, Clinical Cancer Research.

Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals

A. Vincent-Salomon, M. Stern, F. Bidard, 2022, Cancers.

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

F. Bidard, J. Pierga, P. Cottu, 2020, Breast cancer research : BCR.

Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.

E. Winer, T. Fehm, C. Hudis, 2020, Journal of the National Cancer Institute.

Impact of circulating tumor DNA early detection and serial monitoring in the management of stage I to III colorectal cancer.

F. Bidard, D. Bello Roufai, 2019, Annals of translational medicine.

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues

A. Vincent-Salomon, F. Bidard, J. Pierga, 2007, Journal of Clinical Pathology.

International study on inter-reader variability for circulating tumor cells in breast cancer

S. Sleijfer, T. Fehm, E. Perez, 2014, Breast Cancer Research.

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

M. Campone, G. Romieu, F. Bidard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

X. Pivot, F. Bidard, J. Pierga, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating Tumor Cells.

K. Griffith, M. Campone, D. Hayes, 2016, Advances in experimental medicine and biology.

Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients.

F. Reyal, B. Asselain, M. Marty, 2011, Annals of Oncology.

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

M. Konantz, C. Lengerke, J. Gallon, 2022, Communications biology.

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.

M. Campone, F. Bidard, J. Pierga, 2012 .

A covariate‐specific time‐dependent receiver operating characteristic curve for correlated survival data

F. Bidard, A. Latouche, P. Blanche, 2020, Statistics in medicine.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, A. Figer, F. Bidard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.

C. Tournigand, F. Bidard, M. Hebbar, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

P. Neven, R. Steele, A. Vincent-Salomon, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Running title : CTCs and staging in MBC

T. Fehm, C. Caldas, J. Reis-Filho, 2018 .

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

P. Neven, A. Bardia, F. Bidard, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression

André F. Vieira, O. Mariani, A. Vincent-Salomon, 2022, Modern Pathology.

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma

V. Servois, B. Asselain, F. Bidard, 2016, The oncologist.

Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma.

A. Vincent-Salomon, J. Klijanienko, F. Bidard, 2009, European journal of cancer.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

F. Bertucci, F. André, J. Lemonnier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating Tumor Cells in Early Breast Cancer

F. Bidard, J. Pierga, A. Latouche, 2019, JNCI cancer spectrum.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial†

G. MacGrogan, F. Bidard, O. Trédan, 2016 .

Predictive Biomarkers and Personalized Medicine Establishment and Validation of Circulating Tumor Cell – Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients

G. Hortobagyi, A. Giordano, B. Egleston, 2013 .

M. Campone, F. Bidard, J. Pierga, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer

Leonie L. Zeune, F. Bidard, J. Pierga, 2020, Breast Cancer Research.

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.

V. Servois, B. Asselain, F. Bidard, 2015, Cancer letters.

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.

M. Campone, F. Bidard, J. Pierga, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

F. Bidard, J. Pierga, O. Bouché, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Implementing circulating tumor cells in routine practice of breast cancer management: overview of the interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2013 .

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

T. Fehm, C. Caldas, J. Reis-Filho, 2014, The Lancet. Oncology.

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

T. Fehm, C. Caldas, S. Dawson, 2022, The oncologist.

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial

F. Bidard, J. Pierga, A. Gonçalves, 2021, Cancers.

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

M. Espié, F. Bidard, J. Pierga, 2020, JAMA oncology.

Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.

F. Bidard, T. Maudelonde, V. D’Hondt, 2020, Clinical chemistry.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Circulating Tumor Cells, a Tremendous Prognostic Factor in Inflammatory Breast Cancer.

F. Bidard, 2015, Journal of the National Cancer Institute.

Clinical utility of circulating tumor cells in metastatic breast cancer.

F. Bidard, J. Pierga, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumour cells: telling the truth about metastasis

F. Bidard, 2014 .

Circulating tumor cells in breast cancer†

Charlotte Proudhon, F. Bidard, J. Pierga, 2016, Molecular oncology.

Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT‐quantitative PCR in 94 breast cancer patients with a follow up of 9 years

F. Bidard, J. Pierga, P. de Cremoux, 2007, Molecular oncology.

Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

F. André, J. Lemonnier, J. Bonneterre, 2015 .

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .

Abstract P2-01-01: Establishment and validation of circulating tumor cell-based prognostic nomograms in 497 first-line metastatic breast cancer patients

B. Egleston, F. Bidard, J. Pierga, 2012 .

A three dimensional thermoplastic microfluidic chip for robust cell capture and high resolution imaging.

F. Bidard, J. Pierga, I. Draškovič, 2014, Biomicrofluidics.

Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.

F. Bidard, J. Pierga, P. Barrett-Lee, 2009, Cancer treatment reviews.

Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

I. Bièche, F. Clatot, J. Lemonnier, 2020 .

Circulating extracellular vesicles provide valuable protein, but not DNA, biomarkers in metastatic breast cancer

C. Théry, F. Bidard, C. Proudhon, 2022, Journal of Extracellular Biology.

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer

F. Bidard, J. Pierga, L. Cabel, 2019, Journal of breast cancer.

AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan).

F. Cavalli, A. Kuten, M. Aapro, 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.

A. Vincent-Salomon, I. Bièche, F. Clatot, 2022, Analytical chemistry.

A single droplet digital PCR for ESR1 activating mutations detection in plasma

A. Vincent-Salomon, I. Bièche, M. Stern, 2019, bioRxiv.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

B. Asselain, F. Bidard, J. Pierga, 2017, Anticancer research.

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

I. Bièche, F. Clatot, F. André, 2022, The Lancet. Oncology.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

A. Vincent-Salomon, I. Bièche, F. Bidard, 2018, Clinical Cancer Research.

Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

H. Wildiers, J. Canon, F. Bidard, 2020 .

Modeling of mechanical systems using screw-vectors

Stefano Stramigioli, Bernhard Maschke, F.-C. Bidard, 1999 .

Screw-vector bond graphs for the kinestatic and dynamic modeling of multibody systems

Arjan van der Schaft, Bernhard Maschke, F.-C. Bidard, 1994 .

Abstract PD6-6: A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer

P. Fasching, T. Fehm, A. Lucci, 2013 .

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases

A. Viale, J. Reis-Filho, L. Norton, 2017, Clinical Cancer Research.

Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression

André F. Vieira, O. Mariani, A. Vincent-Salomon, 2022, Modern Pathology.

Diffusion-weighted MRI for uveal melanoma liver metastasis detection

V. Servois, F. Bidard, S. Piperno-Neumann, 2015, European Radiology.

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

F. Bidard, J. Pierga, M. Tanguy, 2018, npj Breast Cancer.

Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma

V. Servois, L. Desjardins, M. Stern, 2012, Clinical Cancer Research.

Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?

D. Santi, F. Bidard, L. Cabel, 2021, Annals of translational medicine.

Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients

G. Dhonneur, V. Servois, X. Paoletti, 2020, JNCI cancer spectrum.

Characteristics and outcome of SARS-CoV-2 infection in cancer patients.

G. Dhonneur, V. Servois, X. Paoletti, 2020, medRxiv.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2016, PloS one.

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2015, PloS one.

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

M. Konantz, C. Lengerke, J. Gallon, 2020, Communications Biology.

Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery

F. Bidard, X. Sastre-Garau, M. Antoine, 2015, Journal of experimental & clinical cancer research : CR.

Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa

F. Bidard, J. Pierga, V. Diéras, 2013, Journal of Neuro-Oncology.

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

F. Bidard, J. Pierga, P. Cottu, 2020, Breast Cancer Research.

ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

F. Bidard, J. Pierga, G. Bataillon, 2019, Oncogene.

Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images

A. Salomon, M. Stern, D. Stoppa-Lyonnet, 2021, bioRxiv.

ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing

François-Clément Bidard, Anne Vincent-Salomon, Alexandre Eeckhoutte, 2020, Bioinform..

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

S. Sleijfer, L. Esserman, B. Naume, 2018, Journal of the National Cancer Institute.

Enhancer rewiring in tumors: an opportunity for therapeutic intervention

R. Margueron, F. Bidard, Laia Richart, 2021, Oncogene.

High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies.

M. Stern, F. Bidard, J. Pierga, 2020, Clinical chemistry.

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

B. Taylor, S. Loi, S. Chandarlapaty, 2019, Cancer discovery.

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial

M. Campone, F. Bidard, J. Pierga, 2021, British Journal of Cancer.

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

T. Delozier, M. Campone, T. Petit, 2012, The Lancet. Oncology.

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors

V. Servois, S. Roman-Roman, M. Stern, 2018, Nature Communications.

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.

J. Lindberg, J. Reis-Filho, M. Diehn, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Male breast cancer : genomic profiling 1 The Genomic Landscape of Male Breast Cancers

Melissa P. Murray, Sakr, C. Hudis, 2016 .

HPV circulating tumor DNA to monitor the efficacy of anti‐PD‐1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report

V. Servois, W. Cacheux, I. Bièche, 2017, International journal of cancer.

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions

R. Gray, M. Dowsett, J. Deasy, 2019, JNCI cancer spectrum.

Identification of tissue of origin and guided therapeutic applications in cancers of unknown primary using deep learning and RNA sequencing (TransCUPtomics).

O. Mariani, A. Vincent-Salomon, O. Delattre, 2021, The Journal of molecular diagnostics : JMD.

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

B. Monk, D. Solit, F. Meric-Bernstam, 2019, Gynecologic oncology.

Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse

J. Thiery, A. Vincent-Salomon, F. Bidard, 2008, Clinical Cancer Research.

A DNA methylation-based liquid biopsy for triple-negative breast cancer

M. Stern, F. Bidard, J. Pierga, 2021, npj Precision Oncology.

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer

J. Lemonnier, F. Bidard, J. Pierga, 2021, NPJ breast cancer.

Spatial co-fragmentation pattern of cell-free DNA recapitulatesin vivochromatin organization and identifies tissues-of-origin

A. Schmitt, L. Laurent, Siddarth Selvaraj, 2019 .

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

A. Vincent-Salomon, M. Ychou, M. Stern, 2018, Clinical chemistry.

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

I. Bièche, F. Bidard, J. Pierga, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.

F. Bidard, H. Gortais, E. Jeannot, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris

F. Bidard, N. Escriou, O. Lantz, 2020, medRxiv.

High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection.

François-Clément Bidard, Jean-Louis Viovy, Laurent Malaquin, 2015, Lab on a chip.

Translating metastasis-related biomarkers to the clinic—progress and pitfalls

J. Thiery, J. Soria, F. Bidard, 2013, Nature Reviews Clinical Oncology.

Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions

A. Vincent-Salomon, M. Stern, F. Bidard, 2016, Expert review of molecular diagnostics.

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2012, Cancer and Metastasis Reviews.

Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types

I. Bièche, M. Stern, R. Lebofsky, 2015, Molecular oncology.

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification

A. Vincent-Salomon, R. Rouzier, F. Reyal, 2012, PloS one.

Circulating tumor cells: clinical validity and utility

F. Bidard, J. Pierga, C. Proudhon, 2017, International Journal of Clinical Oncology.

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

J. Grenier, G. MacGrogan, G. MacGrogan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study

F. Bidard, J. Pierga, F. Dalenc, 2021, Breast cancer research : BCR.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

T. Fehm, A. Rademaker, C. Caldas, 2019, Critical reviews in oncology/hematology.

Cancers du sein : chimiothérapie néo-adjuvante Déterminants de la réponse à la chimiothérapie néo-adjuvante dans les cancers du sein Predictors of response to neoadjuvant chemotherapy for breast cancer

F. Reyal, F. Bidard, J. Pierga, 2011 .

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients

Olivier Lantz, Fabian Birzele, Roland Schmucki, 2015, International journal of cancer.

Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers.

S. Michiels, F. André, F. Bidard, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing

M. Berger, J. Reis-Filho, B. Weigelt, 2014, Molecular Oncology.

Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model

François-Clément Bidard, Magali Lacroix-Triki, Olivier Trédan, 2015, Targeted Oncology.

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer

M. Stern, F. Bidard, J. Pierga, 2016, Molecular oncology.

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

I. Bièche, F. Clatot, F. André, 2022, BMJ Open.

Oral etoposide and trastuzumab in HER2-positive metastatic breast cancer: a retrospective study at Institut Curie Hospitals.

A. Vincent-Salomon, M. Stern, F. Bidard, 2022 .

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays

Jean Salamero, François-Clément Bidard, Jean-Louis Viovy, 2010, Proceedings of the National Academy of Sciences.

FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells.

François-Clément Bidard, Jean-Yves Pierga, Jean-Louis Viovy, 2017, Methods in molecular biology.

Cancers du sein : chimiothérapie néo-adjuvante Chimiothérapie néo-adjuvante des cancers du sein Neoadjuvant chemotherapy in breast cancer

F. Reyal, F. Bidard, J. Pierga, 2011 .

Going with the Flow: From Circulating Tumor Cells to DNA

Jorge S. Reis-Filho, J. Reis-Filho, B. Weigelt, 2013, Science Translational Medicine.

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions.

M. Stern, F. Bidard, J. Pierga, 2018, Journal of visualized experiments : JoVE.

Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance

Christophe Lemetre, Ronglai Shen, Charles Swanton, 2014 .

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

J. Bonneterre, M. Campone, T. Petit, 2014, Clinical Cancer Research.

Abstract S6-06: The genomic landscape of male breast cancers

J. Hicks, C. Hudis, J. Reis-Filho, 2015 .

Expanding biomarkers for PARP inhibitors

F. Bidard, F. Coussy, 2022, Nature Cancer.

Circulating tumor cells in breast cancer 5

F. Bidard, J. Pierga, C. Proudhon, 2016 .

Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.

J. Thiery, A. Vincent-Salomon, F. Bidard, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative CT Extent of Lung Damage in COVID-19 Pneumonia Is an Independent Risk Factor for Inpatient Mortality in a Population of Cancer Patients: A Prospective Study

V. Servois, X. Paoletti, F. Bidard, 2020, Frontiers in Oncology.

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

R. Gray, M. Dowsett, J. Deasy, 2019, JNCI cancer spectrum.

Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients

G. Hortobagyi, A. Giordano, B. Egleston, 2013, Clinical Cancer Research.

ESR1 mutations: a new biomarker in breast cancer

F. Bidard, J. Pierga, E. Jeannot, 2019, Expert review of molecular diagnostics.

Abstract S6-06: High-depth massively parallel sequencing reveals heterogeneity between primary tumor and metastatic deposits in de novo metastatic breast cancer patients prior to exposure to systemic therapy

J. Reis-Filho, L. Norton, B. Weigelt, 2013 .

Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1.

T. Delozier, F. André, J. Bonneterre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microsatellite instability detection in breast cancer using drop-off droplet digital PCR

A. Vincent-Salomon, I. Bièche, M. Stern, 2022, Oncogene.

Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.

M. Beckmann, P. Fasching, M. Fernö, 2021, European journal of cancer.

Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer.

A. Vincent-Salomon, F. Bidard, J. Pierga, 2019, International journal of radiation oncology, biology, physics.

Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer.

A. Vincent-Salomon, Y. Rycke, F. Bidard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

A. Vincent-Salomon, R. Rouzier, S. Vacher, 2016, Oncotarget.

Survival of breast cancer patients with meningeal carcinomatosis.

F. Bidard, J. Pierga, V. Girre, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Meningeal carcinomatosis in HER2-overexpressing breast cancers

F. Bidard, J. Pierga, V. Diéras, 2009, Journal of Neuro-Oncology.

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature

N. Girard, F. Bidard, D. Ricard, 2019, Journal of Immunotherapy for Cancer.

[Disseminated and circulating tumor cells in gastrointestinal oncology].

F. Bidard, J. Pierga, P. Mariani, 2012, Bulletin du cancer.

Disseminated and circulating tumor cells in gastrointestinal oncology.

M. Ducreux, F. Bidard, J. Pierga, 2012, Critical reviews in oncology/hematology.

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

Thomas Bachelot, François-Clément Bidard, Mario Campone, 2012, Breast Cancer Research.

International study on inter-reader variability for circulating tumor cells in breast cancer

S. Sleijfer, T. Fehm, E. Perez, 2014, Breast Cancer Research.

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

M. Espié, F. Bidard, J. Pierga, 2019, General Session Abstracts.

Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study

M. Fernö, R. Aft, D. Wallwiener, 2019, General Session Abstracts.

Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centre

F. Bidard, P. Cottu, C. Bouleuc, 2021, BMJ Supportive & Palliative Care.

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study

A. Salomon, V. Servois, I. Bièche, 2021, Genome medicine.

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

M. Campone, F. Bidard, J. Pierga, 2012, Breast Cancer Research.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

M. Espié, D. Cox, R. Rouzier, 2016, Bulletin du cancer.

HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer

R. Rouzier, I. Bièche, F. Bidard, 2021, ESMO open.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma

A. Vincent-Salomon, S. Vacher, A. Lièvre, 2018, Clinical Cancer Research.

Microfluidic extraction and digital quantification of circulating cell-free DNA from serum

F. Bidard, J. Viovy, I. Pereiro, 2019, Sensors and Actuators B: Chemical.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer

Leon W. M. M. Terstappen, Gerhardt Attard, C. Punt, 2013, PloS one.

Abstract OT1-1-10: CirCe T-DM1 phase II trial: Assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1

Y. Rycke, B. Asselain, R. Lebofsky, 2013 .

Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial

B. Asselain, F. Bidard, J. Pierga, 2012 .

Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation.

D. Spector, F. Bidard, M. Egeblad, 2023, Cancer cell.

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

A. Vincent-Salomon, R. Rouzier, H. Brisse, 2020, Breast Cancer Research.

Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma

André F. Vieira, A. Vincent-Salomon, F. Reyal, 2020, Modern Pathology.

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.

F. Penault-Llorca, F. André, F. Bidard, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

P. Neven, A. Bardia, F. Bidard, 2023, Cancer Research.

Fibroblast heterogeneity in solid tumors: from single cell analysis to whole-body imaging.

I. Buvat, F. Bidard, F. Mechta-Grigoriou, 2022, Seminars in cancer biology.

A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ).

V. Servois, L. Desjardins, B. Asselain, 2017 .

BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results.

V. Servois, L. Desjardins, F. Bidard, 2013 .

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

I. Bièche, F. Clatot, F. André, 2022, Cancer Research.

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach

F. Bidard, J. Viovy, S. Descroix, 2022, Cancers.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.

F. Cardoso, T. Petit, F. Bidard, 2020 .

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors

V. Servois, S. Roman-Roman, M. Stern, 2018, Nature Communications.

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

J. Lemonnier, F. Bidard, J. Pierga, 2019, Angiogenesis.

Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

H. Wildiers, A. Guerrero-Zotano, E. Yang, 2022, Cancer Research.

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.

H. Iwata, Yeon-Hee Park, F. Bidard, 2023, Future oncology.

Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial

I. Bièche, F. Clatot, J. Lemonnier, 2019, Annals of Oncology.

BRCA1 germ-line mutation: Predictive of sensitivity to anthracyclin alkylating agents regimens but not to taxanes?

F. André, F. Bidard, M. Spielmann, 2008 .

Circulating tumor cell count and thrombosis in metastatic breast cancer

F. Bidard, J. Pierga, V. Diéras, 2017, Journal of thrombosis and haemostasis : JTH.

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

F. Bidard, J. Pierga, M. Tanguy, 2018, npj Breast Cancer.

Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy?

A. Vincent-Salomon, F. Bidard, L. Cabel, 2022, Journal of the National Cancer Institute.

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study

A. Salomon, V. Servois, I. Bièche, 2021, Genome medicine.

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients

S. Vacher, I. Bièche, F. Bidard, 2019, Cancers.

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

J. Lemonnier, F. Bidard, M. Mouret-Reynier, 2020 .

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

B. Wittner, A. Iafrate, Risa Burr, 2023, Breast Cancer Research and Treatment.

ERBB3-Activating Mutations in Small Bowel Adenocarcinomas.

S. Vacher, I. Bièche, P. Laurent-Puig, 2018, JCO precision oncology.

Circulating tumor DNA detection in hepatocellular carcinoma.

F. Bidard, J. Pierga, B. Buecher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.

J. Lemonnier, F. Bidard, B. Pistilli, 2018 .

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

F. Bidard, J. Pierga, P. Cottu, 2020, Breast cancer research : BCR.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

S. Sleijfer, B. Naume, A. Lucci, 2017 .

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

W. Cacheux, M. Ychou, M. Stern, 2016 .

Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant forHER2-mutant, hormone receptor-positive, metastatic breast cancer

S. Loi, M. Burkard, H. Wildiers, 2021 .

Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis.

D. Larsimont, M. Piccart, F. Bidard, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P2-02-08: Initial circulating tumor cell count and venous thrombosis-free interval in the course of metastatic breast cancer

F. Bidard, J. Pierga, V. Diéras, 2016 .

Effective treatment based on monitoring bESR1 mutations - Authors' reply.

F. Bidard, S. Delaloge, A. Hardy-Bessard, 2023, The Lancet. Oncology.

PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer

F. Bidard, L. Dercle, L. Champion, 2023, Journal of clinical medicine.

[Impact of the COVID-19 epidemic on requests for initial care for breast cancer].

R. Rouzier, F. Bidard, P. Cottu, 2020, Bulletin du cancer.

Transcriptomic Profiles and Circulating Tumor Cell Detection in Primary Breast Cancer.

M. Espié, F. André, F. Reyal, 2009 .

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival

F. Bidard, J. Pierga, O. Trédan, 2017, British Journal of Cancer.

Abstract 4599: Detecting MSI phenotype in circulating blood DNA

I. Bièche, M. Stern, F. Bidard, 2018, Clinical research.

Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal canal carcinoma.

S. Vacher, A. Lièvre, W. Cacheux, 2018 .

Clinical utility of circulating tumor cells in metastatic breast cancer.

F. Bidard, J. Pierga, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P2-01-04: Long term independent prognostic impact of circulating tumor cells detected before neoadjuvant chemotherapy in non-metastatic breast cancer: 70 months analysis of the REMAGUS02 study

A. Vincent-Salomon, M. Marty, F. Bidard, 2012 .

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma

V. Servois, B. Asselain, F. Bidard, 2016, The oncologist.

[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab

I. Buvat, F. Bidard, P. Cottu, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer

I. Buvat, R. Rouzier, F. Bidard, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Clinical utility of circulating tumor cells: an update

F. Bidard, J. Pierga, A. Vasseur, 2020 .

P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

M. Campone, G. Romieu, F. Bidard, 2011 .

Abstract PD2-06: CirculatingESR1mutation detection rate and early decrease under first line aromatase inhibitor and palbociclib in the PADA-1 trial (UCBG-GINECO)

I. Bièche, J. Lemonnier, F. Bidard, 2019, Poster Discussion Abstracts.

Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.

F. Bidard, V. Diéras, V. Quillien, 2023, Clinica chimica acta; international journal of clinical chemistry.

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients

S. Vacher, I. Bièche, F. Bidard, 2019, Cancers.

333PCIRCULATING TUMOR CELL COUNT AT BASELINE IS AN INDEPENDENT PROGNOSTIC FACTOR FROM PATHOLOGICAL COMPLETE RESPONSE AMONG PATIENTS TREATED FOR PRIMARY INFLAMMATORY HER2-POSITIVE BREAST CANCER: SURVIVAL RESULTS OF THE BEVERLY-2 STUDY.

J. Bonneterre, M. Campone, T. Petit, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract OT3-4-05: Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial

B. Asselain, M. Campone, F. Bidard, 2012 .

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

F. Bidard, N. Dohollou, S. Ladoire, 2023, Scientific reports.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, F. Bidard, A. Gramont, 2009, Annals of Oncology.

Circulating tumor cells in breast cancer†

F. Bidard, J. Pierga, C. Proudhon, 2016, Molecular Oncology.

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

J. Bonneterre, M. Campone, T. Petit, 2014, Clinical Cancer Research.

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues

A. Vincent-Salomon, F. Bidard, J. Pierga, 2007, Journal of Clinical Pathology.

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy

N. Girard, M. Stern, F. Bidard, 2018, Nature Reviews Clinical Oncology.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary study Circe 07 of the LAP 07 trial.

F. Bidard, J. Pierga, O. Bouché, 2013 .

Trends in cancer-targeted antibody–drug conjugates

F. Bidard, O. Trédan, 2014, Targeted Oncology.

Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images

A. Salomon, D. Stoppa-Lyonnet, Etienne Decencière, 2022, Cell reports. Medicine.

Non-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons

Chloé-Agathe Azencott, F. Bidard, C. Proudhon, 2024, medRxiv.

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2015, PLoS ONE.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

R. Rouzier, F. Reyal, F. Bidard, 2016, PloS one.

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma

A. Vincent-Salomon, V. Servois, S. Roman-Roman, 2023, Annals of surgery.

Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?

F. Bidard, L. Cabel, Daniel V. Santi, 2024, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2012, Cancer and Metastasis Reviews.

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.

J. Reis-Filho, L. Norton, A. Vincent-Salomon, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database

F. Bidard, A. Vataire, Stephanie H Read, 2024, Breast cancer research and treatment.